Zacks Investment Research lowered shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) from a hold rating to a sell rating in a report published on Wednesday morning, Zacks.com reports.
According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “
A number of other brokerages have also commented on RDHL. Ascendiant Capital Markets set a $23.00 price target on REDHILL BIOPHAR/S and gave the company a buy rating in a research note on Monday, July 8th. WBB Securities raised REDHILL BIOPHAR/S from a buy rating to a strong-buy rating and set a $17.00 price target on the stock in a research note on Friday, July 12th. Finally, ValuEngine raised REDHILL BIOPHAR/S from a sell rating to a hold rating in a research note on Monday, July 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. REDHILL BIOPHAR/S presently has a consensus rating of Buy and a consensus price target of $17.85.
Shares of RDHL stock opened at $6.80 on Wednesday. The company’s 50-day moving average price is $7.05. REDHILL BIOPHAR/S has a 12 month low of $5.13 and a 12 month high of $9.57. The company has a current ratio of 2.84, a quick ratio of 2.71 and a debt-to-equity ratio of 0.10.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.04. REDHILL BIOPHAR/S had a negative return on equity of 93.55% and a negative net margin of 561.47%. The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $2.98 million. Equities analysts predict that REDHILL BIOPHAR/S will post -1.45 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its stake in shares of REDHILL BIOPHAR/S by 69.9% in the fourth quarter. Millennium Management LLC now owns 301,693 shares of the biotechnology company’s stock worth $1,674,000 after acquiring an additional 124,072 shares during the period. Ibex Investors LLC lifted its stake in shares of REDHILL BIOPHAR/S by 3.9% in the first quarter. Ibex Investors LLC now owns 975,928 shares of the biotechnology company’s stock worth $8,110,000 after acquiring an additional 36,914 shares during the period. ARK Investment Management LLC lifted its stake in shares of REDHILL BIOPHAR/S by 8.5% in the first quarter. ARK Investment Management LLC now owns 65,918 shares of the biotechnology company’s stock worth $548,000 after acquiring an additional 5,177 shares during the period. Geode Capital Management LLC acquired a new position in shares of REDHILL BIOPHAR/S in the fourth quarter worth approximately $73,000. Finally, Sanders Morris Harris LLC acquired a new position in shares of REDHILL BIOPHAR/S in the second quarter worth approximately $330,000. 35.63% of the stock is currently owned by institutional investors.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
Featured Article: Cash Flow
Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.